← Back

Medacta Group SA

MOVE.SWCHF
114.20-23.6%1Y · CHF

Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices across Latin America, North America, the Asia-Pacific, and the Middle East and Africa. It offers personalized 3D planning tools for hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.

Price · split & dividend adjusted
News & notes moving MOVE.SW
Switzerland
Aging Population▼

Medacta Group Fair Value Trimmed to CHF 155.17 on Margin and Valuation Caution

Medacta Group's modeled fair value has been trimmed from CHF 167.98 to CHF 155.17, a moderate reset to the price target tracked by investors. The revision reflects a more cautious debate over balancing the company's long term growth story against investment needs and valuation risk. Berenberg reaffirmed a positive stance while trimming its price target to CHF 180 from CHF 185, still above the revised fair value. Deutsche Bank initiated coverage with a Hold rating and a CHF 121 price target, citing growth normalization and the capital required to sustain future expansion. The updated model raised the revenue growth assumption from 10.01% to 13.52%, lowered the net profit margin assumption from 14.46% to 13.19%, adjusted the future P/E from 29.73x to 27.86x, and moved the discount rate from 4.42% to 4.46%.
MOVE.SW ▼DBK.XETRA
Aging Population
About megatrends
Aging Population › Medical Devices for the Aging Body Capital
MOVE.SW · Capital · Negative Fair value trimmed to CHF 155.17 and Berenberg cut its price target to CHF 180 on margin and valuation caution
DBK.XETRA · Capital · Neutral Deutsche Bank initiated coverage on Medacta with a Hold rating and CHF 121 price target, a passing analyst action not about DB itself
Read original ↗
Simply Wall St·2dRead more →
Switzerland
MOVE.SW▲

Medacta H1 2026 Revenue Rises Nearly 10% to EUR368 Million, Confirms 2026 Outlook

Medacta Group SA reported H1 2026 revenue of EUR368 million, up almost 10% at constant currency, with adjusted EBITDA of EUR97 million and a 27.8% margin at constant currency. Net profit came in at EUR42 million, or 11.4% of revenue, while adjusted comparable net profit was EUR49 million versus EUR46 million a year earlier. Gross margin fell to 65.2% from 68.3% on adverse FX, price erosion and unfavorable geographic and product mix, and free cash flow was negative EUR18.6 million as operating cash flow slipped to about EUR56 million from EUR73 million. Regionally, EMEA grew 10%, APAC 13.1%, Latin America 16.4% and North America 7%, while Spine grew just 4.5% amid a strategic refocus on enabling technology and direct sales. Medacta confirmed its 2026 outlook for revenue growth of 10% to 14% and adjusted EBITDA margin expansion of around 50 basis points at constant currency, alongside a midterm revenue CAGR of 12% to 15%.
MEDGF ▲MOVE.SW ▲
MEDGF · Capital · Positive H1 2026 revenue rose nearly 10% to EUR368 million with net profit of EUR42 million and confirmed 2026 outlook.
MOVE.SW · Capital · Positive H1 2026 revenue rose nearly 10% to EUR368 million with net profit of EUR42 million and confirmed 2026 outlook.
Read original ↗
GuruFocus·30dRead more →